Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Clear Guide Medical
With
Temple University
National Institutes of Health (NIH)
This study proposes the use of a new fusion technology, Scenergy (Clear Guide Medical; FDA 510(k) K171677), which fuses CT images to real-time US images to minimize the drawbacks of each modality while enhancing their benefits. Such benefits include, the reduction of radiation dose to the patient with the fusion of initial CT imaging overlaying the live US images. The fused imaging software allows the operator to watch the needle tip advance towards the lesion on both live US and overlaid CT imaging. In such a setting, the operator would only need to perform an initial CT scan, advance the needle into position using fused US/CT images, and a final CT scan to ensure needle tip location. This eliminates interval CT scans that are usually required after each incremental needle position adjustment, and thus, reduces radiation dose to the patient and wasted procedural time during the incremental CT scans.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
all patients between the ages of 18 and 80 years old at time of procedure who are pre-scheduled for a lung, kidney, or liver biopsy.
You may not be if
any patient who was under the age of 18 or over the age of 80 at time of the procedure or who does not wish to volunteer for the study.